Charcot-Marie-Tooth disease (CMT) is the most common inherited neuromuscular disorder worldwide, affecting roughly 1 in 3,300 people, or about 150,000 individuals in the United States alone. When counting all neuromuscular diseases, including those caused by immune system dysfunction rather than genetics, Guillain-Barré syndrome and myasthenia gravis also rank among the most prevalent. The answer depends on whether you’re asking about inherited conditions specifically or the broader category, which includes autoimmune and degenerative diseases.
How Neuromuscular Diseases Are Ranked
Neuromuscular diseases are a large family of conditions that damage the nerves controlling your muscles, the connection point between nerve and muscle, or the muscle tissue itself. A UK study tracking primary care data from 2000 to 2019 found that the overall prevalence of these conditions grew by 63% over two decades, while the rate of new diagnoses stayed roughly constant. That gap reflects better diagnosis and longer survival rather than a true increase in how often these diseases occur.
By lifetime prevalence per 100,000 people, the top conditions in 2019 were Guillain-Barré syndrome (40.1), myasthenia gravis (33.7), muscular dystrophy (29.5), and Charcot-Marie-Tooth disease (29.5, tied with muscular dystrophy). These numbers capture everyone living with a diagnosis, including people who recovered. When looking at new cases diagnosed each year, the ranking shifts: motor neuron disease (which includes ALS) had the highest incidence at 3.4 per 100,000 person-years, followed by myasthenia gravis at 2.5 and Guillain-Barré syndrome at 1.7.
Charcot-Marie-Tooth Disease: The Most Common Inherited Form
CMT damages the peripheral nerves, the long cables that carry signals from your brain and spinal cord out to your hands and feet. Because those distant nerves are affected first, symptoms typically start in the feet and lower legs before progressing to the hands. Weakness in the lower legs leads to difficulty lifting the front of the foot (foot drop), a high-stepped walking pattern, and frequent tripping. Over time, the muscles in the calves and forearms can visibly shrink.
The disease is genetic, with several subtypes that follow different inheritance patterns. The most common form, CMT1, is autosomal dominant, meaning a single copy of the faulty gene from one parent is enough to cause it. Between 70 and 80 percent of CMT1 cases involve an extra copy of a gene called PMP22 on chromosome 17, which disrupts the insulating sheath around nerves. Other forms, like CMT4, require defective genes from both parents, and one type (CMTX) is linked to the X chromosome, which means it tends to affect males more severely.
CMT is not life-threatening in most cases, but it is progressive. Symptoms usually appear in adolescence or early adulthood and worsen gradually over decades. There is no cure, and treatment focuses on physical therapy, bracing, and sometimes surgery to correct foot deformities.
Myasthenia Gravis: The Most Common Autoimmune Type
Myasthenia gravis (MG) is the most common neuromuscular disease caused by the immune system. In MG, antibodies attack the junction where nerves communicate with muscles, blocking the chemical signals that trigger muscle contraction. The hallmark symptom is muscle weakness that worsens with activity and improves with rest. It often starts in the muscles controlling the eyelids and eye movement, causing drooping eyelids or double vision, then may spread to muscles involved in chewing, swallowing, speaking, and breathing.
An analysis of U.S. insurance claims data estimated that roughly 116,000 Americans are living with MG. The condition can develop at any age but has two common windows: younger women in their 20s and 30s, and older men in their 60s and 70s. Mortality data from a large cohort found that 14% of MG patients had died within five years of diagnosis and 21% within ten years. Infections, often linked to long-term use of immune-suppressing medications, were the leading cause of death. About 15 to 20 percent of patients experience a myasthenic crisis at some point, a dangerous flare where breathing muscles weaken enough to require ventilator support.
Life expectancy for people with MG has improved dramatically over the past several decades, though it remains slightly shorter than the general population. Males with MG died on average at 78.3 years compared to a national average of 81.6, and females at 76.5 versus 85.2.
Other High-Prevalence Neuromuscular Diseases
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is the most common and most severe form of muscular dystrophy, affecting about 1 in every 5,000 males between ages 5 and 9. It results from a missing protein called dystrophin that muscles need to stay intact. Boys with DMD typically show signs of weakness by age 3 to 5 and lose the ability to walk during childhood. Without steroid treatment, walking usually stops around age 10. Boys who take steroids for more than five years tend to keep walking until about age 12. A gene therapy called Elevidys, approved by the FDA, delivers a shortened version of the dystrophin gene to muscle cells, though long-term outcomes are still being tracked.
ALS (Motor Neuron Disease)
Amyotrophic lateral sclerosis, or ALS, destroys the motor neurons that control voluntary movement. It has the highest rate of new diagnoses among neuromuscular diseases (3.4 per 100,000 person-years in the UK data), but because it progresses rapidly and is fatal, its prevalence at any given time is lower than slower-progressing conditions. In the U.S., prevalence peaks sharply with age: 0.5 cases per 100,000 in people aged 18 to 39, jumping to 20.2 per 100,000 in those aged 70 to 79. Males are about 1.6 times more likely to develop ALS than females, and whites are affected at more than twice the rate of Black Americans.
How These Conditions Are Diagnosed
Diagnosing neuromuscular diseases typically starts with a combination of blood tests and electrical studies. A blood test for creatine kinase (CK), an enzyme that leaks out of damaged muscle cells, is often the first clue. Elevated levels point toward a dystrophy or other muscle disorder. Electromyography (EMG) and nerve conduction studies remain the best tools for pinpointing where in the motor system the problem lies, whether it’s the nerve, the junction, or the muscle itself.
Muscle and nerve biopsies were historically the gold standard for confirming a specific diagnosis, though genetic testing has increasingly replaced biopsies for inherited conditions like CMT and DMD. Whole-body MRI, particularly muscle MRI, has also emerged as a useful way to map which muscles are affected and track disease progression without an invasive procedure. For autoimmune conditions like myasthenia gravis, blood tests for specific antibodies can often confirm the diagnosis without a biopsy at all.